Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939484 · ClinicalTrials.gov registry record · Phase 2
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT00939484: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00939484 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939484, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and may be an effective treatment for medulloblastoma.
Interventions
- DRUG Vismodegib
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-06 |
| Est. Completion | 2015-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00939484
The ClinicalTrials.gov registry entry for NCT00939484 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vismodegib is the first listed.
NCT00939484 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00939484 about?
NCT00939484 is a clinical study titled "Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma". This phase II trial is studying how well vismodegib works in treating adult patients with recurrent or refractory medulloblastoma. Vismodegib may slow the growth of tumor cells and may be an effective treatment for medulloblastoma.
What is the current status of trial NCT00939484?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2009-06. Estimated completion is 2015-08.
What interventions are being tested in trial NCT00939484?
The interventions under investigation include: Vismodegib (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT00939484?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.